Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT05994625

Economic Evaluation of Stream™ Platform

This Economic Evaluation study is a multi-center, two-arm, non-randomized, interventional trial. The purpose of this study is to evaluate the economic and patient outcomes of using the Stream™ Platform for early detection of anastomotic leakage after gastrointestinal surgery. The trial will track patient outcomes and healthcare costs in two groups: the intervention group, where the Stream platform is deployed, and the control group, before the integration of the Stream™ Platform. The data collected from both groups will be compared to assess the impact of implementing the Stream™ Platform and early leak detection on overall patient outcomes and healthcare costs.This trial will include hepatobiliary, colorectal, and trauma/acute care patient populations.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Conditions

Anastomotic Leak Pathologic Processes Pathological Conditions, Signs and Symptoms Postoperative Complications

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Hamilton General Hospital - Hamilton Health Sciences, Hamilton, Ontario, Canada

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 18 years - Male or Female
  • Subject understands and has voluntarily signed and dated the informed consent form (ICF).
  • Subjects must be willing to comply with trial requirements
  • Subject has performed an open or laparoscopic surgery with peritoneal or pelvic drainage

Exclusion criteria

  • Subject is pregnant
  • Subject will be discharged < 8 hours post-surgery
  • 24 or more have passed since the end of the subject's surgery
  • Involvement in the planning and conduct of the clinical investigation
  • Subject is allergic to contrast medium
  • Participation in another investigational drug or device study which would interfere with the endpoints of this study
  • Device does not attach to drain used on the subject

Treatment and study plan

Stream™ Platform

Device

Stream™ Platform consists of 3 main components: Origin™ , Delta™ Monitor, and Stream™ Application. Origin™ is an inline biosensor system that can be attached inline between an off-the-shelf drainage catheter and reservoir system and is designed to monitor real-time changes in drained effluent characteristics (specifically pH and electrical conductivity (EC)) to identify potential anastomotic leaks. The Stream™ Application is a mobile application for displaying and analyzing data collected continuously via Origin™. Stream™ Application is pre-installed on Android mobile devices (called Delta™ Monitor).

Stream™ Platform utilizes the continuous measurements of drain effluent characteristics to generate a Risk Score that is provided to the surgeon. The Risk Score is intended to provide an additional tool for the early diagnosis of anastomotic leakage.

Stream™ Platform with Risk Score Omitted

Device

Stream™ Platform consists of 3 main components: Origin™ , Delta™ Monitor, and Stream™ Application. Origin™ is an inline biosensor system that can be attached inline between an off-the-shelf drainage catheter and reservoir system and is designed to monitor real-time changes in drained effluent characteristics (specifically pH and electrical conductivity (EC)) to identify potential anastomotic leaks. The Stream™ Application is a mobile application for displaying and analyzing data collected continuously via Origin™. Stream™ Application is pre-installed on Android mobile devices (called Delta™ Monitor).

This version of Stream™ Platform is utilized purely for observational purposes. Therefore, no Risk Score is generated. This allows postoperative monitoring of patients without any influence from the Stream™ Platform.

Other names: NERv's Inline Device

Primary outcomes

  1. Does Stream™ Platform integrate well with the existing clinical workflow (1)?

    Time frame: Through study completion, an average of 1 year

    Quantify average time spent by clinical research coordinator (CRC)/delegate interacting with Stream™ Platform (during attachment, daily calibration, and detachment) in minutes

  2. Does Stream™ Platform integrate well with the existing clinical workflow (2)?

    Time frame: Through study completion, an average of 1 year

    Observe overall compliance to Instructions for use though quantification of the number of daily calibrations completed

  3. Does Stream™ Platform integrate well with the existing clinical workflow (3)?

    Time frame: Through study completion, an average of 1 year

    Quantify the overall reported satisfaction score of the CRC/delegate through surveys.

  4. Does Stream™ Platform reduce the cost of care for anastomotic leak patients in colorectal, hepatobiliary, and trauma and acute care surgeries (1)?

    Time frame: Upon study completion (12 months)

    Quantify the average number of tests and procedures performed to detect anastomotic leakage before and after the implementation of Stream™ Platform.

  5. Does Stream™ Platform reduce the cost of care for anastomotic leak patients in colorectal, hepatobiliary, and trauma and acute care surgeries (2)?

    Time frame: Upon study completion (12 months)

    Quantify the average patient cost/cost of hospitalization and by-department cost (log of all billed items including medications, laboratory investigations, diagnostic/radiology investigations, hospital length of stay, ICU admission, re-admission within 30 days after discharge, time of discharge and therapeutic services) for colorectal, HPB, and trauma and acute care patients before and after the implementation of Stream™ Platform.

  6. Number of Subjects with Device Related Adverse Events

    Time frame: Upon study completion (12 months)

    An adverse event assessment will be performed in accordance to ISO 14155 standards to determine the number of device related adverse events.

Secondary outcomes

  1. Does Stream™ Platform allow for earlier postoperative anastomotic leak detection in colorectal, HPB, and trauma and acute care surgeries compared to clinical judgment/laboratory assessment (1)?

    Time frame: Upon study completion (12 months)

    Quantify the average time to detect anastomotic leakage after colorectal, HPB, and trauma and acute care patients using conventional diagnostic techniques (PRE) and after the implementation of Stream™ Platform (POST).

  2. Does Stream™ Platform allow for earlier postoperative anastomotic leak detection in colorectal, HPB, and trauma and acute care surgeries compared to clinical judgment/laboratory assessment (2)?

    Time frame: Upon study completion (12 months)

    Quantify the average sensitivity, specificity, and overall accuracy of conventional diagnostic techniques for detection of anastomotic leakage after colorectal, HPB, and trauma and acute care surgeries in contrast to the average sensitivity, specificity, and overall accuracy of Stream™ Platform.

  3. Does Stream™ Platform reduce the need for non-conservative management and hospital re-admission that is associated with anastomotic leak patients in colorectal, HPB, and trauma and acute care surgeries (1)?

    Time frame: Upon study completion (12 months)

    a. Quantify the average rate of type of re-intervention due to anastomotic leakage after colorectal, HPB, and trauma and acute care surgeries before and after the implementation of Stream™ Platform.

  4. Does Stream™ Platform reduce the need for non-conservative management and hospital re-admission that is associated with anastomotic leak patients in colorectal, HPB, and trauma and acute care surgeries (2)?

    Time frame: Upon study completion (12 months)

    Quantify the average number of emergency re-admissions within 30 days after discharge due to anastomotic leakage in colorectal, HPB, and trauma and acute care surgeries before and after the implementation of Stream™ Platform.

  5. Does Stream™ Platform reduce adverse events that are associated with anastomotic leak patients in colorectal, HPB, and trauma and acute care surgeries?

    Time frame: Upon study completion (12 months)

    Quantify the average number of adverse events (such as rate of secondary postoperative complications, rate of permanent stoma, 30-day mortality, etc.) due to anastomotic leakage after leakage in colorectal, HPB, and trauma and acute care surgeries before and after the implementation of Stream™ Platform.

Sponsors and collaborators

Lead sponsor

FluidAI Medical

Industry

Collaborators

  • Hamilton Health Sciences Corporation
  • Ontario Bioscience Innovation Organization

Registry information

Official study title

Economic Evaluation of Stream™ Platform for the Early Detection of Anastomotic Leakage After Gastrointestinal Surgery

Acronym: CostAL

Important dates

Study start
2023
Primary completion
2026
Study completion
2026
First posted
Aug 16, 2023
Registry last updated
Mar 13, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.